Agenus (AGEN) on Tuesday swung to Q3 earnings of $0.72 per share from a loss of $0.28 per share a year earlier. Three analysts polled by Capital IQ...
(Updates with share price in second paragraph) Agenus (AGEN) said Friday that it is withdrawing its biologics license application for cervical cancer drug...
Agenus (AGEN) said Friday it is withdrawing its biologics license application for cervical cancer drug candidate balstilimab at the recommendation of the...
Agenus (AGEN) said Tuesday it has triggered a $20 million cash payment under its global licensing agreement with Bristol Myers Squibb (BMY) for AGEN1777 to...
| Address | 3 Forbes Road Lexington, Massachusetts 02421-7305 |
| Phone | +1.781.674.4400 |
| Number of Employees | 294 |
| Recent SEC Filing | 11/12/2021 S-3ASR |
| Chairman & Chief Executive Officer | Garo H. Armen |
| President & Chief Operating Officer | Jennifer S. Buell |
| Chief Financial & Accounting Officer, VP-Finance | Christine M. Klaskin |
| Chief Technology Officer | Marc van Dijk |
| Price Open | $3.01 |
| Previous Close | $3.02 |
| 52 Week Range | $2.50 - 6.79 |
| Market Capitalization | $749.9 M |
| Shares Outstanding | 256.8 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 03/21/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$0.10 |
| Beta vs. S&P 500 | N/A |
| Revenue | $36.8 M |
| Net Profit Margin | 1.30% |
| Return on Equity | -3.00% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
